Amgen Makes $1.16B Bid for BiTE Antibody Firm Micromet
BioWorld Today Contributing Writer
Perhaps the ultimate sign of a satisfied customer is a willingness to pay more than $1 billion for a company after using a product for six months. Having had a taste of Micromet Inc.'s BiTE antibody platform through a license agreement inked July 12, 2011, Amgen Inc., of Thousand Oaks, Calif., offered $1.16 billion to acquire the Rockville, Md.-based company.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST